Differences Between Original Intravenous Iron Sucrose and Iron Sucrose Similar Preparations

 

 Buy Article Permissions and Reprints

Abstract

Iron sucrose (Venofer®; reference) has a good safety record and is prescribed in patients with anaemia and chronic kidney disease worldwide, but various iron sucrose similar (ISS) preparations are now utilized in clinical practice. This study evaluates possible differences between iron sucrose and ISS preparations on haemodynamic and oxidative stress markers in normal rats. 60 male and 60 female Sprague Dawley rats were divided into four groups and assigned to receive commercially available ISS test 1, ISS test 2, reference or isotonic saline solution (control). A single i. v. dose of iron (40 mg/kg) or saline (equivalent volume) was administered after 24 h and every 7 days for 4 weeks. Blood samples were collected for biological assessment of haemoglobin (Hb), serum iron and percentage transferrin saturation (TSAT), and urine samples were collected to investigate creatinine clearance and proteinuria. Animals were sacrificed after receiving an i. v. dose on days 1, 7 and 28, and kidney, liver, and heart homogenates were then collected to determine antioxidant enzyme levels. Tissues were processed using Prussian blue and immmunohistochemistry techniques to identify iron deposits, tissue ferritin and pro-inflammatory markers. Systolic blood pressure was significantly reduced in the ISS groups relative to the reference and control groups after 24 h and on days 7, 14 and 21 (p < 0.05). Creatinine clearance was reduced (p < 0.01) and proteinuria marked (p < 0.01) in the ISS groups at 24 h and on days 7 and 28 relative to the reference and control groups which did not differ throughout the study. Liver enzymes were also increased in the ISS groups at 24 h and on days 7 and 28. Both ISS test 1 and ISS test 2 groups presented a significant increase in catalase, thiobarbituric reactive species, Cu, Zn-superoxide dismutase (CuZnSOD) and glutathione peroxidase activity, and a decrease in glutathione levels (p < 0.01) in the liver, heart and kidney at 24 h and on day 7 relative to the reference and control groups. Serum iron and percentage TSAT were elevated in all groups (except control) (p < 0.01) but no differences in Hb concentration were observed between them. Finally, levels of the proinflammatory markers TNF-α and IL6 were significantly elevated in the ISS groups (liver, heart and kidney) compared with the reference and control groups on day 28 (p < 0.01). These findings suggest significant differences between the reference and ISS test 1/ISS test 2 regarding oxidative stress and the inflammatory responses of liver, heart and kidneys in normal rats. A possible explanation for these observations could be the stability of the iron complex.

• References

• 1 Silverberg DS, Wexler D, Iaina A, Schwartz D. The interaction between heart failure and other heart diseases, renal failure, and anemia. Semin Nephrol. 2006; 26: 296-306
  CrossrefPubMedGoogle Scholar
• 2 Clark SF. Iron deficiency anemia. Nutr Clin Pract. 2008; 23: 128-141
  CrossrefPubMedGoogle Scholar
• 3 Hörl WH. Iron therapy for renal anemia: how much needed, how much harmful?. Pediatr Nephrol. 2007; 22: 480-489
  CrossrefPubMedGoogle Scholar
• 4 Toblli JE, Cao G, Olivieri L, Angerosa M. Comparative study of gastrointestinal tract and liver toxicity of ferrous sulfate, iron amino chelate and iron polymaltose complex in normal rats. Pharmacology. 2008; 82: 127-137
  CrossrefPubMedGoogle Scholar
• 5 Wilson A, Reyes E, Ofman J. Prevalence and outcomes of anemia in inflammatory bowel disease: a systematic review of the literature. Am J Med. 2004; 116: 44S-49S
  PubMedGoogle Scholar
• 6 Silverberg DS, Wexler D, Blum M, Iaina A. The cardio renal anemia syndrome: correcting anemia in patients with resistant congestive heart failure can improve both cardiac and renal function and reduce hospitalizations. Clin Nephrol. 2003; 60: S93-S102
  PubMedGoogle Scholar
• 7 Macdougall IC. The management of anaemia in chronic kidney disease – current and future issues. Eur Ren Geni-tourin Dis. 2006; 35-36
  PubMedGoogle Scholar
• 8 Moniem KA, Bhandari S. Tolerability and efficacy of parenteral iron therapy in hemodialysis patients, a comparison of preparations. Transfus Altern Transfus Med. 2007; 9: 37-42
  CrossrefPubMedGoogle Scholar
• 9 Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst. 1999; 91: 1616-1634
  CrossrefPubMedGoogle Scholar
• 10 Nissenson AR, Goodnough LT, Dubois RW. Anemia: not just an innocent bystander?. Arch Intern Med. 2003; 163: 1400-1404
  CrossrefPubMedGoogle Scholar
• 11 Besarab A. Resolving the paradigm crisis in intravenous iron and erythropoietin management. Kidney Int. 2006; 69: S13-S18
  CrossrefPubMedGoogle Scholar
• 12 Maslovsky I. Intravenous iron in a primary-care clinic. Am J Hematol. 2005; 78: 261-264
  CrossrefPubMedGoogle Scholar
• 13 Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmén J. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant. 2006; 21: 378-382
  CrossrefPubMedGoogle Scholar
• 14 McClellan W, Aronoff SL, Bolton WK, Hood S, Lorber DL, Tang KL et al The prevalence of anemia in patients with chronic kidney disease. Current Medical Research and Opinion. 2004; 20: 1501-1510
  CrossrefPubMedGoogle Scholar
• 15 Aronoff G. Safety of IV iron in haemodialysis patients. Anaemia Network Update. 2004; 3: 2-4
  PubMedGoogle Scholar
• 16 Cichton RC, Danielson BG, Geisser P. Iron therapy with special emphasis. Uni-Med Science. 4th ed 2008. ISBN 978-3-8374-1077-8
  Google Scholar
• 17 Charytan C, Qunibi W, Bailie GR, Venofer Clinical Studies Group. Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients with chronic kidney disease not on dialysis. Nephron Clin Pract. 2005; 100: C55-C62
  CrossrefPubMedGoogle Scholar
• 18 Fishbane S. Safety in iron management. Am J Kidney Dis. 2003; 41: S18-S26
  PubMedGoogle Scholar
• 19 Silverberg DS, Blum M, Agbaria Z, Deutsch V, Irony M, Schwartz D et al The effect of i. v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period. Clin Nephrol. 2001; 55: 212-219
  PubMedGoogle Scholar
• 20 Charytan C, Levin N, Al-Saloum M, Hafeez T, Gagnon S, Van Wyck DB. Efficacy and safety of iron sucrose for iron deficiency in patients with dialysis-associated anemia: North American clinical trial. Am J Kidney Dis. 2001; 37: 300-307
  CrossrefPubMedGoogle Scholar
• 21 Locatelli F. Section III. Treatment of renal anaemia. Ne-phrolDial Transplant. 2004; 19: iil6-ii31
  PubMedGoogle Scholar
• 22 Reed J, Charytan C, Yee J. The safety of intravenous iron sucrose use in the elderly patient. Consult Pharm. 2007; 22: 230-238
  CrossrefPubMedGoogle Scholar
• 23 Macdougall IC. Strategies for iron supplementation: oral versus intravenous. Kidney Int. 1999; 55: S61-S66
  CrossrefPubMedGoogle Scholar
• 24 McCord JM. Human disease, free radicals, and the oxidant/antioxidant balance. Clin Biochem. 1993; 26: 351-357
  CrossrefPubMedGoogle Scholar
• 25 Zanen AL, Adriaansen HJ, van Bommel EFH, Posthuma R, de Jong GM. ‘Oversaturation’ of transferrin after intravenous ferric gluconate (Ferrlecit®) in haemodialysis patients. Nephrol Dial Transplant. 1996; 11: 820-824
  CrossrefPubMedGoogle Scholar
• 26 Venofer PI 2003, Vifor (International) Inc.
  PubMed
• 27 Geisser P, Baer M, Schaub E. Structure/histotoxicity relationship of parenteral iron preparations. Arzneimittelforschung. 1992; 42: 1439-1452
  PubMedGoogle Scholar
• 28 Danielson BG, Salmonson T, Derendorf H, Geisser P. Pharmacokinetics of iron(III)-hydroxide sucrose complex after a single intravenous dose in healthy volunteers. Arzneimittelforschung. 1996; 46: 615-621
  PubMedGoogle Scholar
• 29 Danielson BG. Structure, chemistry, and pharmacokinetics of intravenous iron agents. J Am Soc Nephrol. 2004; 15: S93-S98
  PubMedGoogle Scholar
• 30 Toblli JE, Stella I, de Cavanagh E, Angerosa M, Inserra F, Ferder L. Enalapril prevents tubulointerstitial lesions by hyperoxaluria. Hypertension. 1999; 33: 225-231
  CrossrefPubMedGoogle Scholar
• 31 Akerboom TP, Sies H. Assay of glutathione, glutathione disulfide, and glutathione mixed disulfides in biological samples. Methods Enzymol. 1981; 77: 373-382
  PubMedGoogle Scholar
• 32 Rossi R, Cardaioli E, Scaloni A, Amiconi G, Di Simplicio P. Thiol groups in proteins as endogenous reductans to determine glutathione-protein mixed disulphide in biological systems. Biochim Biophys Acta. 1995; 1243: 230-238
  CrossrefPubMedGoogle Scholar
• 33 United States Pharmacopeial Convention. Iron Sucrose Injection. In: The United States Pharmacopeia: The National Formulary. United States Pharmacopeial Convention Committee of Revision. 2007 pp 1179
  PubMedGoogle Scholar
• 34 Agarwal R, Rizkala AR, Bastani B, Kaskas MO, Leehey DJ, Besarab A. A randomized controlled trial of oral versus intravenous iron in chronic kidney disease. Am J Nephrol. 2006; 26: 445-454
  CrossrefPubMedGoogle Scholar
• 35 Sav T, Tokgoz B, Sipahioglu MH, Deveci M, Sari I, Oymak O et al Is there a difference between the allergic potencies of the iron sucrose and low molecular weight iron dextran?. Ren Fail. 2007; 29: 423-426
  CrossrefPubMedGoogle Scholar
• 36 Zamora E, Lupón J, Urrutia A, González B, Mas D, Diez C et al Estimated creatinine clearance: a determinant prognostic factor in heart failure. Med Clin (Barc). 2008; 131: 47-51
  PubMedGoogle Scholar
• 37 Ozdemir A, Yalinbasss B, Selamet U, Eres M, Murat B, Gürsu RU et al Relationship between iron replacement and hepatic functions in hepatitis C virus-positive chronic haemo-dialysis patients. Nephrology (Carlton). 2005; Oct 10: 433-437
  CrossrefPubMedGoogle Scholar
• 38 Giannini EG, Testa R, Savarino V. Liver enzyme alteration: a guide for clinicians. CMAJ. 2005; 172: 367-379
  CrossrefPubMedGoogle Scholar
• 39 Zager RA. Parenteral Iron Compounds: Potent oxidants but mainstays of anemia management in chronic renal disease. Clin J Am Soc Nephrol. 2006; 1: S24-S31
  CrossrefPubMedGoogle Scholar
• 40 Van Wyck D, Anderson J, Johnson K. Labile iron in parenteral iron formulations: a quantitative and comparative study. Nephrol Dial Transplant. 2004; 19: 561-565
  CrossrefPubMedGoogle Scholar
• 41 Bishu K, Agarwal R. Acute injury with intravenous iron and concerns regarding long-term safety. Clin J Am Soc Nephrol. 2006; 1: S19-S23
  CrossrefPubMedGoogle Scholar
• 42 Chandler G, Harchowal J, Macdougall IC. Intravenous iron sucrose: establishing a safe dose. Am J Kidney Dis. 2001; 38: 988-991
  CrossrefPubMedGoogle Scholar
• 43 Lim P-S, Wei Y-H, Yu YL, Ko B. Enhanced oxidative stress in haemodialysis patients receiving intravenous iron therapy. Nephrol Dial Transplant. 1999; 14: 2680-2687
  CrossrefPubMedGoogle Scholar
• 44 Roob JM, Khoschsorur G, Tiran A, Horina J, Holzer H, Winklhofer-Roob BM. Vitamin E attenuates oxidative stress induced by intravenous iron in patients on hemodialysis. J Am Soc Nephrol. 2000; 11: 539-549
  PubMedGoogle Scholar
• 45 Maher P, Lewerenz J, Lozano C, Torres JL. A novel approach to enhancing cellular glutathione levels. J Neuro-chem. 2008; [epub ahead of print]
  PubMedGoogle Scholar
• 46 Rahman I, MacNee W. Oxidative stress and regulation of glutathione in lung inflammation. Eur Respir J. 2000; 16: 534-554
  CrossrefPubMedGoogle Scholar
• 47 Kudo H, Suzuki S, Watanabe A, Kikuchi H, Sassa S, Sakamoto S. Effects of colloidal iron overload on renal and hepatic siderosis and the femur in male rats. Toxicology. 2008; 246: 143-147
  CrossrefPubMedGoogle Scholar